Revisiting Immunotherapy in Endometrial Cancer

H&O  What are the limitations of chemotherapy for endometrial cancer? RE  The management of endometrial cancer has long relied on cytotoxic chemotherapy alone. This approach was […]

The Emerging Use of Antibody-Drug Conjugates in Ovarian Cancer

H&O  Which patients with ovarian cancer are eligible for treatment with an antibody-drug conjugate (ADC)? DR  The only ADC that has received US Food and Drug […]

Update on Strategies for Platinum-Resistant Ovarian Cancer

H&O How common are primary and secondary resistance to platinum therapy in ovarian cancer? BP Primary resistance to platinum occurs in approximately 20% of patients with […]

Maintenance Therapy With PARP Inhibition in Ovarian Cancer

H&O  Which poly(ADP-ribose) polymerase (PARP) inhibitors are approved for use as maintenance therapy in ovarian cancer?  TH  Two PARP inhibitors are approved for use as frontline […]

Should Secondary Cytoreduction Be Used in Recurrent Ovarian Cancer?

H&O  What is the rationale behind secondary cytoreduction in recurrent ovarian cancer?  SNW  The goal of upfront optimal cytoreduction is to improve outcomes—both progression-free survival (PFS) […]

HIPEC in Ovarian Cancer: Hip or Hype?

H&O  What does hyperthermic intraperitoneal chemotherapy (HIPEC) involve? LR  HIPEC is always used in conjunction with cytoreductive surgery, in which a maximal effort is made to […]

When in the Treatment Continuum to Use PARP Inhibition in Ovarian Cancer

H&O  What are the phases of the treatment of ovarian cancer in which poly(ADP-ribose) polymerase (PARP) inhibitors can be considered? MRM  PARP inhibitors can be considered […]

Update on the Role of Surgery in the Management of Advanced Epithelial Ovarian Cancer

Abstract: Surgical cytoreduction and platinum/taxane-based chemotherapy are the cornerstones of the management of advanced ovarian cancer; however, the optimal timing and order of these interventions remain […]

Highlights in Ovarian Cancer From the American Society of Clinical Oncology Annual Meeting

  H&O  First, let’s talk about secondary cytoreduction. Could you describe the DESKTOP III trial, and what makes it so important? TH  The DESKTOP III trial, […]

PARP Inhibition in Recurrent Ovarian Cancer

  Abstract: With the introduction of PARP inhibitors into frontline chemotherapy, with or without bevacizumab, the hope exists that more women may be spared a recurrence […]

PARP Inhibition as Frontline Therapy in Ovarian Cancer

  Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have been rapidly integrated into clinical practice for women with ovarian cancer. Currently, PARP inhibitors are approved as frontline maintenance […]

The Current Status of Secondary Cytoreduction in Ovarian Cancer: A Systematic Review

  Abstract:  Purpose: Ovarian cancer causes more deaths than any other cancer of the female genital tract. Despite improvements in management and treatment, survival remains low […]

Update on Drugs in Advanced Ovarian Cancer 

  H&O  What is the prognosis for patients with ovarian cancer, and how has it changed in recent years? DO  Ovarian cancer is usually diagnosed at […]

The Role of Maintenance Therapy in Ovarian Cancer

  H&O  What is the rationale behind maintenance therapy in ovarian cancer? AO  The general idea behind maintenance therapy is to keep the cancer under control […]

Management of Rare Epithelial Ovarian Cancers 

  H&O  What percentage of ovarian cancers are epithelial? DG  Approximately 90% of all invasive ovarian cancers are epithelial. The other 2 major categories of invasive […]

Enhanced Recovery After Surgery for Ovarian Cancer

  H&O  What are the protocols that constitute enhanced recovery after surgery (ERAS) in ovarian cancer?  SD  The precise protocols vary somewhat among institutions, but they […]

Management of Epithelial Ovarian Cancer

  H&O  Is surgery always possible in patients with epithelial ovarian cancer?  ML  Surgery is an integral part of the management of epithelial ovarian cancer. Sometimes […]

Management of Newly Diagnosed or Recurrent Ovarian Cancer

  Abstract: The treatment of newly diagnosed or recurrent ovarian cancer has changed significantly in recent years, with an increased number of treatment options available. Surgery […]

Immunotherapy in Ovarian Cancer: Where Are We Now, and Where Are We Going? 

  H&O  What types of immunotherapy have been investigated for use in women with ovarian cancer? AJ  The 3 broad areas of immunotherapy that have been […]

Optimal Treatment for Platinum-Sensitive Recurrent Ovarian Cancer

  H&O  How common is ovarian cancer? BJM  The American Cancer Society estimates that ovarian cancer will be diagnosed in 22,440 women and that 14,080 women […]